Journal of Population Therapeutics & Clinical Pharmacology

REVIEW ARTICLE
DOI: 10.53555/jptcp.v30i19.3751

ARTIFICIAL INTELLIGENCE IN CARDIOVASCULAR DISEASES: A SYSTEMIC REVIEW AND META-ANALYSIS

Jawad Qammar[1*], Muhammad Muneeb[2], Emad Munir[3], Muhammad Nabeel Javed[4], Rohma Ahmad Javed[5], Bilal Qammar[6]

[1*]University of Engineering and Technology, Taxila- Pakistan,
E-mail:- jawad.qammar@students.uettaxila.edu.pk
[2]Assistant Professor and Head of Department Cardiology, Shalamar Hospital, Lahore – Pakistan,
E-mail:- muhammed.muneeb@gmail.com
[3]Shalamar Hospital, Lahore - Pakistan, E-mail:- emad_munir@yahoo.com
[4]Shalamar Hospital, Lahore - Pakistan, E-mail:- rnabeel98@gmail.com
[5]Shalamar Hospital, Lahore – Pakistan, E-mail:- rohmajaved@gmail.com
[6]Shalaar Hospital, Lahore - Pakistan, E-mail:- bilal.qamar.5680@gmail.com

***Corresponding Author:** Jawad Qammar
*University of Engineering and Technology, Taxila – Pakistan,
E-mail:- Jawad.qammar@students.uettaxila.edu.pk

Abstract
AI has developed remarkable growth in the recent years and it has now gained importance in the area of cardiovascular disease. This study will focus on the role of cardiovascular disease and how AI is contributed towards it. So, the Systematic Literature review and meta-analysis will be done.

Key words: Cardiovascular disease, Artificial intelligence.

1. Introduction

Artificial intelligence (AI) has made significant contributions to the field of cardiovascular disease. AI applications encompass a range of areas including diagnosis, risk prediction, and treatment planning. As stated by Alizadehsani et al. (2021) machine learning algorithms can analyze vast amounts of medical data, including patient records, images, and genetic information, to enhance the understanding and management of cardiovascular conditions.

2. Method

This study involves the systematic review and meta-analysis that are based on guidelines described in the study of Ismagilove et al. (2020). The goal of this paper is to evaluate the systematic literature review (SLR) and meta-analysis based on the secondary studies. Moreover, a systematic review is a summary of medical research that employs defined and repeatable processes to search for, critically assess, and synthesise information on a given topic.

2.1: Research Question

Following is the research question that is answered in this systematic literature review.

- RQ: How the Artificial Intelligence (AI) is contributing towards the cardiovascular disease.

2.2: Search Process

The data were searched with the use of a manual searching process that mainly focus upon the journal papers from Pubmed, Research Gate, The European Heart Journal, Springer, Yonsei medical journal, and Taylor and Francis from 2018 to 2023. However, the SLR involve the keywords like "cardiovascular disease", "Artificial intelligence (AI). The data was searched manually, with a particular emphasis on journal papers published between 2018 and 2023. Table 1 shows the journals that were chosen for the purpose of this comprehensive review of the literature. Likewise, it was assured that all publications included appeared relevant to the research issue, and a keyword search approach was used for obtaining the necessary data.

Table 1: Selected Sources (Source: author)

Source	Acronym
Pubmed	Pubmed
Taylor and Francis	T &F
Research Gate	Research Gate
The European Heart Journal	The European Heart Journal
Springer	Springer
Yonsei medical journal	Yonsei medical journal

2.3: Inclusion and Exclusion Criteria

This literature review and meta-analysis has been conducted based on the peer-reviewed articles that were published between 2018-2023. Also, the papers that were based on the literature surveys along with pre-defined research questions were included. So, the included papers are those that serves the prime objective of this SLR. Moreover, the literature review and meta-analysis are the main element of this SLR. On the contrary, based on the upcoming factors the research paper has been excluded from this literature review:

- Research papers that have been published rather than in the English language.
- Research papers that were becoming the constraints in the prime objective of this research.
- Research papers that were published before the year 2018 has been excluded from this research.
- Data that were collected from the informal resource like Wikipedia, Yahoo, Bing, Encyclopedia.
- Hence, the studies within this research were determined with the use of PRISMA methodology. So, below figure 1 explains the PRISMA methodology for this systematic literature review and meta-analysis.



Figure 1: Prisma Flow Chart Diagram

2.4: Quality Assessment

Based on the specific criteria, the quality assessment of the selected papers was induced in this systematic literature review. The criteria defined in the research of Costal et al. (2021) has been induced to perform the quality assessment of the selected papers.

- QA1.All the literature search has covered relevant studies.
- QA2. The quality and validity have been assessed by the reviewers.
- QA3. Appropriate inclusion and exclusion are addressed.

2.5: Data Collection

The data collection has been done after the collecting the qualitative journal articles from different data bases. All those journal articles were based on the SLR and meta-analysis. More certainly, the information was gathered from a variety of databases (see table 1), from which a number of articles were extracted to answer the research topic. On the other hand, the inclusion and exclusion criteria were used to filter the papers, and the research question was answered correctly.

2.6: Data Analysis

Systematic Literature Review and meta-analysis (PRISMA) has been used in the research. A meta-analysis is a quantitative, formal, epidemiological study design that is used to systematically examine the findings of prior research in order to draw conclusions about that body of work.

3. Results

3.1: Search Results

The SLR were from different databases.

Table 2: Result for the Research has been determined after the SLR

Year	2018	2019	2020	2021	2022	2023
Research Gate	4	2	0	2	2	4
The European Heart Journal	0	0	0	1	0	0
Springer	2	2	3	5	2	4
Yonsei Medical Journal	1	1	1	1	2	1
Pubmed	1	1	1	1	1	3

3.2: Quality evaluation of meta-analysis and Systematic Literature Review

Table 3: Quality Evaluation of meta-analysis and Systematic Literature Review

Study	Article Type	QA1	QA2	QA3	Total Score	Initial Rate Agreement
1.	Meta- analysis	yes	Yes	yes	3.5	4
2.	Systematic LR	partly	Partly	yes	3	3
3.	Systematic LR	yes	Partly	partly	3	4
4.	Systematic LR	partly	Partly	Yes	3	4
5.	Meta- analysis	yes	Yes	yes	4	4

3.3: Quality Factors

The quality factors of this research are based on the association with the quality score for the systematic literature review determined by the type of the material that was included in this publication. Table 4 discusses the median quality score than was calculated according to the research findings included in this article.

The formula for calculating the standard deviation is as follows:
$SD=N\sum(Xi-X^{-})2$

Where:
X - is the average of the quality ratings,
Xi- Each unique quality score is represented,
∑-The total of the squared disparities between each quality score and the mean is denoted as,
N represents the total number of studies.

Table 4: Quality Factors Analysis (Source: Author)

Factors	2018	2019	2020	2021	2022	2023
No of studies	1	2	3	12	8	4
Mean quality score	1	1	2	1	8	3
Standard deviation of quality score	1	1	3	4	8	2

4. Systematic Literature Review

Table 5: Summary Table

Reference	Author	Year	Focus	Main Findings
1	Alsharqi, M. et al.	2018	AI and Echocardiography	AI applications in echocardiography
2	Baashar, Y. et al.	2022	AI Models for CVD Prediction	Network meta-analysis on AI models
3	Bachtiger et al.	2022	AI in heart failure screening	Prospective study on AI-enabled screening
4	Bonkhoff et al.	2022	Precision Medicine in stroke	Use of AI for personalized outcome predications
5	Chen et al.	2022	AI in prehospital care	AI- assisted detection of myocardial infarction
6	Dell'Angela et al.	2022	AI in cardiovascular imaging	Critical focus on AI in echocardiography
7	Ghanayim et al.	2022	AI based stethoscope	Diagnosis of aortic stenosis with AI-based stethoscope
8	Grun et al.	2021	AI in cardiovascular medicine	Meta-analysis on AI in heart failure detection
9	Haq et al.	2022	AI in cardiovascular medicine	Current insights and future prospects
10	Jone et al.	2022	AI in congenital heart disease	Current state and prospects
11	Kwon et al.	2020	AI for mitral regurgitation	Detection using electrocardiography
12	Lareyre et al.	2022	AI in non-cardiac vascular disease	Bibliographic analysis of AI applications
13	Li et al.	2022	AI for cardiovascular diseases from wearable devices	Systematic review and meta-analysis
14	Li et al.	2020	AI for left atrial enlargement	Pilot study on AI application in veterinary radiology
15	LV et al.	2021	AI-assisted auscultation	Detecting congenital heart disease with AI
16	Mathur et al.	2020	AI and cardiovascular disease	Overview of AI and machine learning
17	Nedadur et al.	2022	AI for valvular heart disease	Echocardiographic assessment using AI
18	Ranka et al.	2021	AI in cardiovascular medicine	Role of AI in cardiovascular medicine
19	Ribeiro et al.	2022	AI in structural heart disease	Future prospects of AI in transcatheter interventions

20	Roy et al.	2022	AI for valvular heart disease	Classifier identification using deep learning
21	Roy et al.	2019	AI in STEMI interventions	Refining interventions using AI
22	Sameer Mehta et al.	2020	Role of AI in echocardiography	AI applications in echocardiography
23	Singh et al.	2019	AI for valvular heart disease	Mobile solution for early detection
24	Siontis et al. 2021	2021	AI-enhanced electrocardiography	Role of AI in ECG for cardiovascular disease
25	Thoenes et al.	2021	AI in aortic valve disease	Review of AI applications on aortic valve disease
26	Ueda et al.	2023	AI for classifying cardiac functions	Multi-institutional study on AI classification
27	Wang et al.	2021	AI in acute coronary	Literature review of AI applications
28	Xu et al.	2020	AI in multimodality	State of the art review on AI applications
29	Yasmin, F. et al.	2021	AI in Heart Failure Diagnosis	Past present and future of AI in heart failure
30	Alizadehsani et al.	2021	AI for CAD detection	Survey of trends, geographical differences and diagnostic features

Grun et al (2021) in article "identifying Heart failure in ECG Data with Artificial intelligence—a meta-analysis" present the review of the contemporary situation on applying the artificial intelligence in the initial identification of the heart failure utilising ECG data. Grun et al. (2021) conducted the meta-analysis on several research promising findings in respect to using of AI algorithms for heart failure detection. Moreover, the results determine that the AI based systems explains the high level of precision and vulnerability in distinct ECG patterns linked with heart failure. More likely, the accuracy and sensitivity have the ability to serve as the valuable tool for timely and precise diagnosis that allow for early intervention and greater management of heart failure patients. Grun et al. (2021) stresses the need for more validation and standardisation of AI models in order to improve their clinical value.

Moreover, Sameer et al. (2019) in article "Artificial Intelligence: refining STEMI interventions- a systematic review and meta-analysis" interrogate the use of AI in amending interventions for STEMI. Thereby, it highlighted AI ability to increase STEMI diagnosis and patient outcomes importantly. Moreover, it can be assumed that AI systems recognise STEMI patterns in electrocardiograms (ECGs) with high accuracy, allowing for a more rapid and exact treatment. Furthermore, Sameer et al. (2019) suggested that as a result, vital procedures that involve percutaneous coronary intervention, also known as PCI, or thrombolytic medications can be initiated more quickly. The systematic research emphasises the vital role AI might have in expediting STEMI care, eventually decreasing death rates and increasing cardiac medical treatment efficiency.

The article of Chen et al. (2022) "Artificial intelligence assisted remote detection of ST-elevation myocardial infarction using a mini-12-lead electrocardiogram device in pre-hospital ambulance care: System review and meta-analysis" it bestowed the significant understanding of the function of AI in the distant identification of STEMI in pre-hospital paramedic care using the transportable ECG monitors. Thereby, it depicted by Chen et al. (2022), AI-augmented STEMI detection in pre-hospital environments has an opportunity to transform immediate action and enhance the treatment of patients. It nevertheless serves to underline the requirement for additional research and standardisation of artificial intelligence to guarantee their continued resilience and dependability. Hence, the investigation highlights AI's revolutionary influence in pre-hospital STEMI

identification, anticipating a future in which advanced technology plays a key role in enhancing the timeliness and reliability of immediate medical care for patients with cardiovascular disease.

In clinical scenarios, according to Lareyre et al. (2022) AI systems have demonstrated the ability to assist in early detection of heart diseases by analyzing electrocardiograms (ECGs) and other diagnostic data. Lareyre et al. (2022) further elaborated that they can also help identify at-risk patients through predictive analytics, enabling proactive interventions and personalized treatment plans. Moreover, as per Lareyre et al. (2022) AI aids in image analysis, improving the accuracy of cardiac imaging like echocardiography and MRI, thus enabling more precise diagnoses. Also, it has been argued by Lareyre et al. (2022) AI approaches have demonstrated the ability to expedite the detection and treatment of cardiovascular illnesses (CVDs), such as heart failure, atrial fibrillation, valvular heart disease, hypertrophic cardiomyopathy, congenital heart disease, and others in the clinical setting, AI has been shown to be beneficial in CVD diagnosis, improving the efficiency of auxiliary tools, disease classification and type, and predicting outcomes. Recent AI algorithms, which have been deeply developed to capture tiny correlations from huge amounts of healthcare data, are projected to tackle more difficult duties than previous approaches.

Baashar et al. (2022) in his article "Effectiveness of AI models for cardiovascular disease prediction: network Meta-analysis, a systematic review and meta-analysis" show that artificial intelligence algorithms have shown substantial potential in adequately forecasting the risk of cardiovascular disease. Furthermore, Seetharam, Raina and Sengupta (2020) argued that AI's reliance on the reliability and the accuracy of training data generates bias, ultimately leading to erroneous recommendations. So, this becomes especially important in healthcare, because differences in data collecting might unintentionally prolong existing disparities. The study demonstrates the superior performance of certain artificial intelligence models, illuminating whether one is more effective when it comes to of accuracy and precision. Nevertheless, as per Jone et al. (2022), the seamless integration of AI into existing practises requires conquering resistance from medical personnel who may be wary of changes to conventional workflows. So, this opposition is exacerbated by ambiguities about the role of AI in the process of decision-making, needing careful negotiation in adoption tactics. Also, Baashar et al. (2022) explains that it emphasis the possibility of artificial intelligence as a powerful risk assessment tool, allowing for prompt intervention and targeted preventative action. The findings highlight AI's revolutionary possibilities in cardiovascular healthcare, with a primary objective of improving the results for patients and lowering the financial burden associated with cardiovascular illnesses.

Siontis et al. (2021) wrote the article "Artificial intelligence-enhanced electrocardiography in Cardiovascular disease management: a systematic review and meta-analysis" depicts that the use of artificial intelligence (AI) to enhance cardiovascular management using better ECG. It can be assumed by Li et al. (2020), the difficulty in understanding problem with AI algorithms is a key impediment to their general adoption in clinical practise. Bachtiger et al. (2022) emphasises the importance of being open in the decisions that are made of these machine learning algorithms in order to foster trust among healthcare practitioners. Clinicians must understand how AI reaches its judgements in order to properly incorporate its results into their methods for making choices. More likely, it can be depicted that the meta-analysis and systematic review highlight AI's ability to improve the accuracy and specificity of ECG interpretations, resulting in more precise and timely actions. On the contrary, Xu et al. (2020) stated that a major concern is the ethical usage of patient data. Because AI relies largely on huge datasets for training, protecting patient privacy and data security is critical. So, to retain patient trust and keep moral guidelines in the use of AI in cardiovascular care, thorough compliance to confidentiality laws and the installation of comprehensive security protocols are required. Also, this technology has great promise for improving patient care, expediting diagnosis, and possibly decreasing the impact of heart failure on both health care systems and people. As per Ueda et al. (2023), the hurdles connected with

integrating AI effectively into medical processes. Healthcare personnel used to traditional practises may be resistant to AI adoption. To overcome this opposition, intensive training program emphasising the benefits of AI and illustrating how it can be utilised in practical problems clinical circumstances are required. Siontis et al. (2021) found that the meta-analysis and systematic review highlight AI's ability to improve the accuracy and specificity of ECG interpretations, resulting in more precise and timely actions. This technology has great promise for improving patient care, expediting diagnosis, and possibly decreasing the impact of heart failure on both health care systems and people.

The article regarding "Artificial intelligence for detection of Cardiovascular-related disease from wearable devices: a systematic review and meta-analysis. More particularly, Lee et al. (2022) suggested that the significance of AI in the early diagnosis of cardiovascular illnesses through portable devices. Lee et al. (2022) stated that explanable AI (XAI) approaches are being developed as part of efforts to improve interpretability. Also, XAI intends to increase the transparency of AI models by providing details about how they apply logic. Moreover, integrating such strategies into AI systems could assist to overcome the accessibility gap, boosting trust and acceptability among healthcare professionals who may be hesitant of depending on opaque techniques elsewhere. So, the results highlight the ability of artificial intelligence to transform cardiac therapy. Furthermore, the research presented here emphasises AI's revolutionary effects on personalised medical care, highlighting its potential to improve early detection and aggressive treatment for heart disease. Lee et al. (2022) suggested that the outcomes point to a promising scenario in which AI and sensors work together to improve cardiovascular disease identification and treatment of patients.

Krittanawong et al. (2017) argued in the article "Artificial Intelligence in Precision Cardiovascular Medicine" suggested that AI is important potential in enhancing customise cardiac care. Roy, Roy and Mandal (2022) supported that AI applications make a substantial contribution to the preparation of treatments. The ability to detect irregularities early enables prompt treatment, preventing the evolution of cardiovascular diseases. As per, the Kwon et al. (2020) study demonstrates how AI's superior ability in detecting minor deviations converts into significant discoveries for healthcare providers, allowing them to conduct therapies only if required. More likely, the findings underscore AI's enormous potential for improving personalised cardiac treatment. AI models are highly accurate in terms of risk prediction, diagnosis, and therapy suggestions. Also, the meta-analysis and systematic review highlight AI's transformational significance in personalising cardiovascular therapy to particular patient demands. Moreover, Ghanayim et al. (2022) argued that the requirement for precise criteria to control the use of AI in medical environments. As technology evolves at a rapid pace, guaranteeing compliance to principles of ethics, patient privacy, including information safety remains increasingly important. Perhaps, Krittanawong et al. (2017) suggested that this kind of equipment guarantees more effective actions, fewer false positives, and better outcomes for patients. Also, it foreshadows a future in which AI could have a critical role in transforming the environment of heart disease treatment, improving precision, and eventually saving lives.

The article "Artificial intelligence in Cardiovascular disease" in which Ranka et al (2021) discusses that AI-powered methods and algorithms have shown great promise in forecasting risks, evaluation, and therapy optimisation. According to the systematic review, AI may improve the accuracy and efficiency of heart disease care, resulting in enhanced outcomes for patients. It can be assumed by Mathur, Srivastava and Mehta (2020), artificial intelligence helps with treatment optimisation by analysing patient reactions to different treatments. AI algorithms can change treatment regimens based on current patient information through ongoing surveillance and data analysis. More particularly, this ever-evolving method assures that therapies are successful and that they may be quickly modified in accordance with altering patient situations. More likely, it can be analysed that these outcomes foreshadow a period in which AI will be crucial to cardiovascular medicine, improving precision, lowering healthcare costs, and potentially revolutionising the way heart

diseases are identified and managed. Hence, Ranka et al (2021) determined that the findings highlight AI's transformational significance in this industry. AI-powered instruments and algorithms have shown great promise in risk prediction, diagnosis, and therapy optimisation.

Yasmin et al. (2021) in the article "Artificial intelligence in the diagnosis and detection of heart failure: the past, present and furture- a systematic review and meta-analysis" dig in the role of artificial intelligence in the diagnosis and detection of heart failure. It suggested that AI has made significant progress in properly detecting cardiac failure. More particularly, Lv et al. (2021) emphasis that AI has the ability to transform the treatment of cardiovascular disease. From early identification to personalised treatment options, the advantages promise to improve patient outcomes and streamline healthcare operations. Yasmin et al. (2021) article shows that artificial intelligence has the potential to improve diagnostic accuracy, streamline the discovery of heart failure trends in medical data, and improve the overall healthcare process. These findings show that artificial intelligence (AI) will play a critical role in redefining the landscape of heart failure diagnosis and detection, with the possibility of early therapies and better patient outcomes.

Furthermore, as per Nedadur et al. (2022) AI plays a role in treatment optimization by assisting in drug selection and dosage adjustments based on individual patient profiles. In surgical procedures, AI-based robotic systems can enhance precision and reduce the invasiveness of interventions. More likely, this is important since AI may be applied to the massive amounts of data created throughout patient care, including as medical evaluations, imaging, and biochemical tests. The focus of AI in the field of heart valve disorders has been on echocardiographic monitoring and profiling of individual patient segments in order to recognise those at greatest risk. Hence, Nedadur et al. (2022) emphasis that AI might integrate echocardiographic measures with different clinical information for precision medical care of congenital cardiac disease sufferers.

Whilst further emphasising upon the advantages on AI in cardiovascular disease, Bonkhoff and Grefkes (2022) stated in their article "that AI classification solutions could be employed in additional situations where rheumatic evaluation on echo is difficult, such as recognising low-flow, low-gradient AS or diseases assessment in mixed valve disease. On the contrary, Ribeiro et al. (2022) stated that notwithstanding its prospective benefits, incorporating AI in coronary artery disease care has its own set of hurdles and drawbacks. Issues with comprehension and explication are important roadblocks. Moreover, certain AI algorithms' 'black-box' character raises issues about comprehending processes for making decisions, hampering the creation of confidence among healthcare practitioners and perhaps preventing wider implementation. Ultimately, AI can improve the implementation of echocardiography during medical procedures by allowing for improved cardiovascular disease discovery, assessment, and management, allowing a greater number of patients to receive swift, precise, and focused on objectives medication. More likely, Bonkhoff and Grefkes (2022) depicted that AI-powered echo automation can lower institutional and fiscal barriers to VHD care, expanding access to screening for diseases, point-of-care cardiac evaluation, and even recommendation for treatment.

The further evidence of benefits of AI in cardiovascular disease has been gathered from the article of Wang et al. (2021) "Application of AI in Acute Coronary Syndrome: a brief literature review", AI's outstanding efficacy in early identification is defined by its ability to sort across large datasets quickly and with extreme accuracy. Unlike traditional approaches, AI systems excel at detecting complex trends even when there are no obvious symptoms. This capacity is especially important in situations when early detection might drastically affect the trajectory of illness advancement. More likely, Wang et al. (2021) argued that the early detection of these modest anomalies not only improves the diagnostic result but also provides the door to preemptive and personalised intervention techniques. Hence, early therapies based on data generated by AI have the potential to impede the advancement of CVD, reduce difficulties, and improve the results for patients.

The research of Alsharqi et al. (2018), in the article "Artificial intelligence and echocardiography" involve to the expanding amount of research justifying the use of AI into clinical procedures, emphasising AI's supportive position alongside healthcare personnel. Although AI can help with diagnosis, human experience is still required for evaluating results in order to make accurate choices about patient treatment. On the other hand, Thoenes et al. (2021) stated that AI-based models for risk assessment that include many patient characteristics to estimate the likelihood of cardiovascular events are being developed. More likely, Singh and Singh (2019) recognise that these models enable healthcare providers to recognise people at greatest risk, allowing preventive actions and therapies to be personalised to each the patients specific risk assessment. Furthermore, AI algorithms' success in early detection through coronary imaging predicts an age of change in cardiovascular care. Alsharqi et al. (2018), the results of the research demonstrate the chance of AI to revolutionise the recognition of inconsistencies related to CVD, providing a revolutionary strategy that permits rapid and precise treatment, and eventually leads to beneficial patient satisfaction and a healthier cardiovascular system.

According to Dell'Angela and Nicolosi (2022), in the article "Artificial intelligence applied to cardiovascular imaging, a critical focus on echocardiography" it can be assumed that cardiovascular radiography has played an important role in the treatment of cardiovascular disorders. Also, the benefits of echocardiography in this industry include broad availability, flexibility, and its accessibility at a low cost. More particularly, AI aids in the development of personalised treatment plans. Ribeiro et al. (2022) offer studies demonstrating how AI-driven algorithms, exploiting significant patient data, aid in the development of personalised treatment strategies. Nevertheless, in contrast to different cardiopulmonary imaging approaches, echocardiographic analysis necessitates exceptionally skilled technicians and indicates considerable spectator uncertainty. More likely, Dell'Angela and Nicolosi (2022) argued that when contrasted with other cardiovascular imaging modalities, echocardiographic evaluation necessitates highly trained operators and implies considerable viewer variability. AI also considerably improves the efficiency of data analysis, as proved by the work of Ueda et al. (2023), rapid examination of large datasets allows healthcare practitioners to make well-informed choices quickly, which is especially important in emergency circumstances whenever speed is of the importance. This level of efficiency is crucial in enhancing the outcomes of patients and optimising healthcare workflows. As a result, artificial intelligence could be immensely beneficial. Considering the perspective of a possible communicated hospitalisation.

In the article "Artificial Intelligence in Cardiovascular Medicine: Current Insights and Future Prospects" by Haq et al. (2022), Cardiovascular disease (CVD) is a major and growing burden on medical facilities. Also, Artificial intelligence (AI) is a fast-expanding multidisciplinary discipline that uses methods based on machine learning (ML) to replicate human senses in order to provide affordable and scalable approaches for better overseeing CVD. Also, Xu et al. (2020), using machine learning approaches, they reveal an unrivalled capacity to rapidly and precisely analyse large datasets, discovering nuanced irregularities suggestive of early-stage cardiovascular disorders. This early discovery lays the foundation for prompt intervention, allowing healthcare providers to implement preventative measures prior to the disease worsens. More likely, enhanced diagnostic and predictive ability enabled by machine learning algorithms are improving clinical care for patients suffering from valvular cardiac conditions and coronary artery diseases. AI has enormous promise in early detection, which is critical in cardiovascular health. Seetharam, Raina and Sengupta (2020) investigated the superior efficacy of AI algorithms in recognising minor anomalies linked with CVD via cardiac magnetic resonance imaging. Haq et al. (2022) suggested that the advancement of AI approaches is not without its limitations, the most significant of which being the necessity for further external evaluation using multicenter, controlled research. Hence, utilising mechanised cardiac monitoring, AI systems can improve the capacity for diagnosis and make clinical decisions.

5. Discussion

As per Jone et al. (2022), as the use of AI in cardiovascular care grows more common, the necessity for strong regulatory frameworks gets more obvious. Kwon et al. (2020) stress the significance of clear rules for AI implementation in healthcare settings. Regulatory agencies must define criteria for artificial intelligence creation, validation, and implementation that prioritise principles of ethics, security for patients, and information protection. Moreover, to incorporate the ongoing surveillance and upgrading of AI systems to stay up with technological breakthroughs and changing healthcare needs. Establishing an environment for regulation that encourages innovation while maintaining ethical norms is critical for realising AI's full promise in cardiovascular care. Also, the advantages of introducing AI into cardiovascular treatment are numerous, ranging from early detection and personalised treatment techniques to increased analysis of information efficiency. However, issues like ethics, comprehension, and incorporation into therapeutic operations must be carefully managed. More particularly, Ghanayim et al. (2022) stated that collaboration among academics, physicians, politicians, and regulatory agencies is essential for establishing a structure that leverages the possibilities of AI while respecting ethical norms and guaranteeing equitable healthcare delivery. AI in cardiovascular medicine has a bright future if these difficulties are tackled methodically and properly.

Partnership between AI developers and healthcare practitioners is required for successful integration. Involving physicians in the development process makes sure that AI corresponds to their workflow demands, transforming it from a barrier to a beneficial tool. AI solutions that are tailored to fit easily into established clinical practises increase adoption and promote an easier shift to AI-driven approaches. Alsharqi et al. (2018) mentioned that AI in cardiovascular medicine entails not just tackling technological obstacles, but also an international viewpoint, concerns about ethics, and a patient-centered strategy.

6. Conclusion

By keeping in mind, the above discussion, it could be concluded that artificial intelligence in cardiovascular disease holds promise in revolutionizing the diagnosis, risk assessment, and treatment of heart-related conditions by leveraging advanced algorithms to process and interpret diverse clinical data sources, ultimately leading to more effective patient care and improved outcomes. The advancement of AI technologies in this field has enormous potential, and sustained multidisciplinary work is required to traverse the complicated environment of healthcare delivery and maximise the benefits of AI for patients with cardiovascular disease around the world.

Concluding that, it is significant that to ensure the appropriate and inclusive incorporation of AI in cardiovascular care, however, obstacles relating to interpretability, accuracy of data, and moral issues must be handled. As the area evolves, collaboration among studies, physicians, and policymakers is critical to realising AI's full promise and raising the quality of heart attack management.

7. References

1. Alizadehsani, R., Khosravi, A., Roshanzamir, M., Abdar, M., Sarrafzadegan, N., Shafie, D., ... & Acharya, U. R. (2021). Coronary artery disease detection using artificial intelligence techniques: A survey of trends, geographical differences and diagnostic features 1991–2020. Computers in Biology and Medicine, 128, 104095.
2. Alsharqi, M., Woodward, W.J., Mumith, J.A., Markham, D.C., Upton, R. and Leeson, P., 2018. Artificial intelligence and echocardiography. Echo Research & Practice, 5(4), pp.R115-R125.
3. Baashar, Y., Alkawsi, G., Alhussian, H., Capretz, L. F., Alwadain, A., Alkahtani, A. A., & Almomani, M. (2022). Effectiveness of artificial intelligence models for cardiovascular disease prediction: network meta-analysis. Computational intelligence and neuroscience, 2022.

4. Bachtiger, P., Petri, C.F., Scott, F.E., Park, S.R., Kelshiker, M.A., Sahemey, H.K., Dumea, B., Alquero, R., Padam, P.S., Hatrick, I.R. and Ali, A., 2022. Point-of-care screening for heart failure with reduced ejection fraction using artificial intelligence during ECG-enabled stethoscope examination in London, UK: a prospective, observational, multicentre study. The Lancet Digital Health, 4(2), pp.e117-e125.
5. Bonkhoff, A.K. and Grefkes, C., 2022. Precision medicine in stroke: towards personalized outcome predictions using artificial intelligence. Brain, 145(2), pp.457-475.
6. Chen, K. W., Wang, Y. C., Liu, M. H., Tsai, B. Y., Wu, M. Y., Hsieh, P. H., ... & Chang, K. C. (2022). Artificial intelligence-assisted remote detection of ST-elevation myocardial infarction using a mini-12-lead electrocardiogram device in prehospital ambulance care. Frontiers in Cardiovascular Medicine, 9, 1001982.
7. Costal, D., Farré, C., Franch, X., & Quer, C. (2021). How tertiary studies perform quality assessment of secondary studies in software engineering. arXiv preprint arXiv:2110.03820.
8. Dell'Angela, L. and Nicolosi, G.L., 2022. Artificial intelligence applied to cardiovascular imaging, a critical focus on echocardiography: The point-of-view from "the other side of the coin". Journal of Clinical Ultrasound, 50(6), pp.772-780.
9. Ghanayim, T., Lupu, L., Naveh, S., Bachner-Hinenzon, N., Adler, D., Adawi, S., Banai, S. and Shiran, A., 2022. Artificial intelligence-based stethoscope for the diagnosis of aortic stenosis. The American Journal of Medicine, 135(9), pp.1124-1133.
10. Grün, D., Rudolph, F., Gumpfer, N., Hannig, J., Elsner, L. K., von Jeinsen, B., ... & Keller, T. (2021). Identifying heart failure in ECG data with artificial intelligence—a meta-analysis. Frontiers in Digital Health, 2, 584555.
11. Haq, I.U., Chhatwal, K., Sanaka, K. and Xu, B., 2022. Artificial intelligence in cardiovascular medicine: current insights and future prospects. Vascular Health and Risk Management, pp.517-528.
12. Jone, P.N., Gearhart, A., Lei, H., Xing, F., Nahar, J., Lopez-Jimenez, F., Diller, G.P., Marelli, A., Wilson, L., Saidi, A. and Cho, D., 2022. Artificial Intelligence in Congenital Heart Disease: Current State and Prospects. JACC: Advances, 1(5), p.100153.
13. Kwon, J.M., Kim, K.H., Akkus, Z., Jeon, K.H., Park, J. and Oh, B.H., 2020. Artificial intelligence for detecting mitral regurgitation using electrocardiography. Journal of electrocardiology, 59, pp.151-157.
14. Lareyre, F., Lê, C. D., Ballaith, A., Adam, C., Carrier, M., Amrani, S., ... & Raffort, J. (2022). Applications of artificial intelligence in non-cardiac vascular diseases: a bibliographic analysis. Angiology, 73(7), 606-614.
15. Lee, S., Chu, Y., Ryu, J., Park, Y. J., Yang, S., & Koh, S. B. (2022). Artificial intelligence for detection of cardiovascular-related diseases from wearable devices: a systematic review and meta-analysis. Yonsei medical journal, 63(Suppl), S93.
16. Lee, S., Chu, Y., Ryu, J., Park, Y.J., Yang, S. and Koh, S.B., 2022. Artificial intelligence for detection of cardiovascular-related diseases from wearable devices: a systematic review and meta-analysis. Yonsei medical journal, 63(Suppl), p.S93.
17. Li, S., Wang, Z., Visser, L.C., Wisner, E.R. and Cheng, H., 2020. Pilot study: application of artificial intelligence for detecting left atrial enlargement on canine thoracic radiographs. Veterinary radiology & ultrasound, 61(6), pp.611-618.
18. Lv, J., Dong, B., Lei, H., Shi, G., Wang, H., Zhu, F., Wen, C., Zhang, Q., Fu, L., Gu, X. and Yuan, J., 2021. Artificial intelligence-assisted auscultation in detecting congenital heart disease. European Heart Journal-Digital Health, 2(1), pp.119-124.
19. Mathur, P., Srivastava, S., Xu, X. and Mehta, J.L., 2020. Artificial intelligence, machine learning, and cardiovascular disease. Clinical Medicine Insights: Cardiology, 14, p.1179546820927404.
20. Nedadur, R., Wang, B., & Tsang, W. (2022). Artificial intelligence for the echocardiographic assessment of valvular heart disease. Heart, 108(20), 1592-1599.

21. Ranka, S., Reddy, M., & Noheria, A. (2021). Artificial intelligence in cardiovascular medicine. Current Opinion in Cardiology, 36(1), 26-35.
22. Ribeiro, J.M., Astudillo, P., de Backer, O., Budde, R., Nuis, R.J., Goudzwaard, J., Van Mieghem, N.M., Lumens, J., Mortier, P., Mattace-Raso, F. and Boersma, E., 2022. Artificial intelligence and transcatheter interventions for structural heart disease: a glance at the (near) future. Trends in cardiovascular medicine, 32(3), pp.153-159.
23. Roy, T.S., Roy, J.K. and Mandal, N., 2022. Classifier identification using deep learning and machine learning algorithms for the detection of valvular heart diseases. Biomedical Engineering Advances, 3, p.100035.
24. Sameer Mehta, M. D., Mario Alberto Torres, M. D., Isabella Vallenilla, M. D., Maria Angelica Marin, M. D., Maria Isabel Acosta, M. D., Claudia Lopez, M. D., ... & Benjamin Wood, M. D. (2019). Artificial Intelligence: Refining STEMI Interventions.
25. Seetharam, K., Raina, S. and Sengupta, P.P., 2020. The role of artificial intelligence in echocardiography. Current Cardiology Reports, 22, pp.1-8.
26. Singh, K.K. and Singh, S.S., 2019, July. An Artificial Intelligence based mobile solution for early detection of valvular heart diseases. In 2019 IEEE International Conference on Electronics, Computing and Communication Technologies (CONECCT) (pp. 1-5). IEEE.
27. Siontis, K. C., Noseworthy, P. A., Attia, Z. I., & Friedman, P. A. (2021). Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. Nature Reviews Cardiology, 18(7), 465-478.
28. Thoenes, M., Agarwal, A., Grundmann, D., Ferrero, C., McDonald, A., Bramlage, P. and Steeds, R.P., 2021. Narrative review of the role of artificial intelligence to improve aortic valve disease management. Journal of Thoracic Disease, 13(1), p.396.
29. Ueda, D., Matsumoto, T., Ehara, S., Yamamoto, A., Walston, S.L., Ito, A., Shimono, T., Shiba, M., Takeshita, T., Fukuda, D. and Miki, Y., 2023. Artificial intelligence-based model to classify cardiac functions from chest radiographs: a multi-institutional, retrospective model development and validation study. The Lancet Digital Health, 5(8), pp.e525-e533.
30. Wang, H., Zu, Q., Chen, J., Yang, Z. and Ahmed, M.A., 2021. Application of artificial intelligence in acute coronary syndrome: a brief literature review. Advances in Therapy, pp.1-9.
31. Xu, B., Kocyigit, D., Grimm, R., Griffin, B.P. and Cheng, F., 2020. Applications of artificial intelligence in multimodality cardiovascular imaging: a state-of-the-art review. Progress in cardiovascular diseases, 63(3), pp.367-376.
32. Yasmin, F., Shah, S. M. I., Naeem, A., Shujauddin, S. M., Jabeen, A., Kazmi, S., ... & Lak, H. M. (2021). Artificial intelligence in the diagnosis and detection of heart failure: the past, present, and future. Reviews in Cardiovascular Medicine, 22(4), 1095-1113.